About Theranexus

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.

Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

Theranexus raises around 3.1 million euros in fundraising

11/07/2023 - 07.30 AM CET

Download PDF File (<1Mo)

Theranexus launches a global offering for an amount of c. 4 million euros and welcomes the American Beyond Batten Disease Foundation as a new shareholder

11/07/2023

Download PDF File (<1Mo)

Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)

14/06/2023 7.30 AM CET

Download PDF File (<1Mo)

Theranexus and BBDF granted positive opinion by EMA for the design of Phase III trial to evaluate Batten-1 in CLN3 Batten disease

07/06/2023 7.30 AM CET

Download PDF File (<1Mo)

Theranexus and BBDF win FDA approval on efficacy endpoints for the Phase III trial to
evaluate Batten-1 in CLN3 Batten disease

09/05/2023 7.30 AM CET

Download PDF File (<1Mo)